(XBI) S&P Biotech - Overview
ETF Category: Health | Exchange: NYSE (USA) | Market Cap: 8.150m USD | Total Return: 53.3% in 12m
Avg Turnover: 1.02B
Warnings
No concerns identified
Tailwinds
No distinct edge detected
The SPDR S&P Biotech ETF (XBI) tracks the S&P Biotechnology Select Industry Index, utilizing a sampling strategy to replicate the performance of the biotechnology segment within the broader S&P Total Market Index. The fund maintains a policy of investing at least 80% of its total assets in the constituent securities of its benchmark index. Unlike many market-cap-weighted funds, this ETF follows an equal-weighted methodology, which provides higher exposure to small and mid-cap companies within the sector.
The biotechnology sector is characterized by high research and development (R&D) intensity and a business model often reliant on the clinical trial success of proprietary drug candidates. Companies in this space frequently engage in strategic partnerships or acquisitions with larger pharmaceutical firms to fund late-stage development and commercialization. Investors can utilize ValueRay to further analyze the underlying holdings and valuation metrics of this ETF. Established in 2006, XBI serves as a primary benchmark for liquid exposure to the U.S. biotech industry.
- Interest rate cuts drive capital flows into small-cap biotech
- M&A activity increases as pharmaceutical giants face patent cliffs
- FDA drug approval rates influence speculative clinical-stage valuations
- Funding environment improves as venture capital and secondary offerings stabilize
As of June 08, 2026, the stock is trading at USD 128.67 with a total of 8,385,179 shares traded.
Over the past week, the price has changed by -5.87%,
over one month by -3.73%,
over three months by +1.22% and
over the past year by +53.25%.
S&P Biotech has no consensus analysts rating.